Filing Flows › Comparisons › CRBU vs CGON
Caribou Biosciences vs CG Oncology: CRBU and CGON compared
Caribou Biosciences is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.6M for CG Oncology (Q3 2026). CG Oncology is growing faster (-4% against -27% a year earlier).
Where the money goes: CRBU and CGON
Caribou Biosciences (CRBU) · Q3 2026
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart follows the revenue to costs, profit and cash.
CG Oncology (CGON) · Q3 2026
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart follows the revenue to costs, profit and cash.
| Caribou Biosciences (CRBU) | CG Oncology (CGON) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.6M | $1.6M |
| Revenue growth, Y/Y | -27% | -4% |
| Operating margin | n/m | n/m |
| Net earnings | −$26.6M | −$56.9M |
| Operating cash flow | −$22.5M | −$47.7M |
Questions
Which is bigger, Caribou Biosciences or CG Oncology?
Caribou Biosciences is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.6M for CG Oncology (Q3 2026).
Is Caribou Biosciences or CG Oncology growing faster?
CG Oncology is growing faster (-4% against -27% a year earlier).
More: Caribou Biosciences earnings · how Caribou Biosciences makes money · CG Oncology earnings · how CG Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.